S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
pixel
pixel
pixel
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
pixel
pixel
pixel
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
pixel
pixel
pixel
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
pixel
pixel
pixel
Log in
OTCMKTS:CBIS

Cannabis Science Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$0.0050
0.00 (0.00 %)
(As of 11/27/2019)
Add
Compare
Today's Range
$0.01
Now: $0.01
$0.01
50-Day Range
$0.01
MA: $0.01
$0.01
52-Week Range
$0.00
Now: $0.01
$0.06
VolumeN/A
Average Volume4.85 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Cannabis Science, Inc., together with its subsidiaries, develops, produces, and commercializes phytocannabinoid-based pharmaceutical products primarily in the United States. The company is developing medicines for autism, blood pressure, cancer, cancer side effects, and other illnesses, as well as for general health maintenance. Its drugs under development include CS-TATI-1 for newly diagnosed and treatment-experienced patients with drug-resistant HIV strains, as well as those intolerant of available therapies; CS-S/BCC-1 to treat basal and squamous cell carcinomas; and a proprietary cannabis-based therapy for neurological conditions. In addition, the company offers an online video-based medical cannabis education system, including courses, such as medical cannabis law, benefits of medical marijuana, cooking, horticulture, and bud tending; and manufactures and distributes specialty horse and pet grooming and topical applications. It has collaboration with IGXBio, Inc. to develop GenePro, a DNA-based immunotherapeutic drug; and a research collaboration agreement with Dana-Farber Cancer Institute, Inc. to develop and investigate the use of cannabinoids to cure various cancers, as well as with Stellenbosch University to treat chronic pelvic pain associated with pelvic inflammatory disease in women, chronic prostatitis in men, and other chronic pain associated with other indications. The company was formerly known as Gulf Onshore, Inc. and changed its name to Cannabis Science, Inc. in April 2009. The company was incorporated in 1996 and is based in Irvine, California. Cannabis Science, Inc. is a subsidiary of Weedmaps Media, Inc.
Cannabis Science logo

Headlines

CBIS Invests in Future Growth of the Midwest Team
October 8, 2020 |  prnewswire.com
CBIS - Building a Culture that Aligns with Our Values
June 17, 2020 |  www.prnewswire.com
65 Outstanding Black And Hispanic Men Leading In Cannabis
December 26, 2019 |  finance.yahoo.com
Cannabis Science enters transition stage as shares halted
September 6, 2019 |  seekingalpha.com
NHS Industries Partners with Cannabis Science and...
August 28, 2019 |  www.benzinga.com
Cannabis Science Partners With CDN Firm NHS...
August 28, 2019 |  www.benzinga.com
See More Headlines

Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryCannabis
SectorMedical
Current SymbolOTCMKTS:CBIS
CUSIP137648101
Phone+1-888-8890888
EmployeesN/A
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Next Earnings DateN/A
OptionableNot Optionable

MarketRank

Overall MarketRank

0.52 out of 5 stars

Medical Sector

1487th out of 1,969 stocks

Drug Manufacturers - Specialty & Generic Industry

44th out of 61 stocks

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Receive CBIS News and Ratings via Email

Sign-up to receive the latest news and ratings for CBIS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Cannabis Science (OTCMKTS:CBIS) Frequently Asked Questions

What stocks does MarketBeat like better than Cannabis Science?

Wall Street analysts have given Cannabis Science a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Cannabis Science wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Cannabis Science's earnings last quarter?

Cannabis Science Inc (OTCMKTS:CBIS) released its quarterly earnings results on Tuesday, July, 28th. The company reported $0.00 earnings per share for the quarter.
View Cannabis Science's earnings history
.

Who are Cannabis Science's key executives?

Cannabis Science's management team includes the following people:
  • Mr. Raymond C. Dabney, Co-Founder, Chairman, CEO & Pres (Age 54)
  • Mr. Benjamin C. K. Tam, CFO, Sec. & Director (Age 67)
  • Mr. Robert James Kane, COO & Director (Age 43)
  • Mr. Mario Lap, Pres of European Operations & Director (Age 67)
  • Mr. Bret Bogue, Director of Horticulture and Head of R&D

Who are some of Cannabis Science's key competitors?

What other stocks do shareholders of Cannabis Science own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cannabis Science investors own include Medical Marijuana (MJNA), (CGC), Terra Tech (TRTC), 22nd Century Group (XXII), Hemp (HEMP), Aurora Cannabis (ACBFF), Cronos Group (CRON), Aurora Cannabis (ACB), KushCo (KSHB) and Energous (WATT).

What is Cannabis Science's stock symbol?

Cannabis Science trades on the OTCMKTS under the ticker symbol "CBIS."

What is Cannabis Science's stock price today?

One share of CBIS stock can currently be purchased for approximately $0.01.

What is Cannabis Science's official website?

The official website for Cannabis Science is www.cannabisscience.com.

Where are Cannabis Science's headquarters?

Cannabis Science is headquartered at 19800 Macarthur Blvd Ste 300, IRVINE, CA 92612-2479, United States.

How can I contact Cannabis Science?

Cannabis Science's mailing address is 19800 Macarthur Blvd Ste 300, IRVINE, CA 92612-2479, United States. The company can be reached via phone at +1-888-8890888.


This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.